P16.05 Exploratory Study of Sintilimab Intrapleural Therapy for NSCLC-Mediated Malignant Pleural Effusion

T. Lv,G. Wu,X. Song,X. Li,J. Zhang,Y. Song
DOI: https://doi.org/10.1016/j.jtho.2021.01.551
IF: 20.121
2021-01-01
Journal of Thoracic Oncology
Abstract:NSCLC-mediated malignant pleural effusion (MPE) severely restricts the quality of life and renders a poor prognosis, and intrapleural therapy plays an important part in the treatment. Our previous studies have revealed that tumor-derived exosomes highly express PD-L1 and play a role in immune-escape and promoting MPE formation, therefore injecting anti-PD-1 locally may bring clinical benefits. In our pre-clinical MPE model, mice were responsive to anti-PD-1 treatments, resulting in reduced volume of MPE.
What problem does this paper attempt to address?